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Dear Editor, 
Tuberous sclerosis (TS) is an autosomal dominant 
multisystem disease, which occurs due to genetically 
determined hyperplasia of ectodermal and mesoder-
mal cells. Clinical manifestations present on the skin 
and in the nervous system, kidneys, heart, and other 
organs. Recent studies estimate the incidence of TS 
at 1/6000 to 1/10,000 live births, and a prevalence in 
the general population of approximately 1 in 20,000 
(1). There are two different genetic loci responsible 
for TS: 9q34 (TSC1-hamartin) and 16p13.3 (TSC2-tu-
berin) (2). Cutaneous manifestations occur in about 
96% of patients (3). Neurological disorders occur in 
50% of patients in the form of seizures and motor and 
psychomotor symptomatology (4). 
A 19-year-old male patient was hospitalized for 
clinical and diagnostic evaluation in February 2016 
year in Clinic for Nephrology, Clinical Center of Mon-
tenegro, Podgorica, Montenegro. Polycystic kidney 
changes were verified by ultrasound when the pa-
tient was three years old, with the presence of several 
calcified nodules in lateral ventricles and supraven-
tricularly in the brain as well as the existence of sev-
eral hypopigmented maculae on the skin. During the 
last hospitalization in February 2016, the following 
tests were performed: cranial magnet resonance im-
aging (MRI) findings showed the existence of visible 
changes in the signal in the form of ectopic tuber tis-
sue in the region of the cortex and subcortical white 
matter of the brain, but without neurological and psy-
chomotor abnormalities; ultrasound of the urinary 
tract showed that both kidneys were enlarged with 
multiple cysts, with dominant cysts at the lower pole 
of the right kidney with a size of 55 mm and at the 
upper pole of the left kidney, approximately 40 mm. 
Reduced functional capacity of kidneys was found 
on dynamic scintigraphy, slightly more in the left 
kidney (41%) compared with the right (59%). Electro-
encephalography, X-ray of the lungs and heart, and 
echocardiography were also performed, but without 
any pathological findings.  
Dermatological examination found numerous fi-
broma up to 0.5 cm in diameter, the largest located 
nasolabially, periorally, and on the chin skin (Figure 
1) at the age of seven, whereas a fibroma and several 
white maculae were present from birth on the skin 
of the forehead. They were now also present on the 
skin of the trunk and on the upper and lower ex-
tremities (Figure 2), accompanied by surrounding 
Figure 1. Facial angiofibromas. Figure 2. Hypomelanotic macules.
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minor changes in the form of confetti-like maculae. 
A subungual fibroma was present on the third finger 
of the right hand. Collagen nevus (shagreen patch) 
(5), i.e. a subepidermal fibrosis as a mildly elevated, 
palm-sized area is also characteristic of TS, which is 
described in literature, in most cases in the lumbosa-
cral region. In our case, such a fibrosis about 3 cm in 
diameter, and with the consistency of an orange peel, 
was discovered on the right shoulder. Subungual fi-
bromas (Koenen tumors) (6), which can develop in 
adolescence, were present in our patient on the third 
finger of the right hand.
The diagnosis of TS was established based on ge-
netic testing, physical examination, ultrasound-veri-
fied polycystic kidney disease and reduced global re-
nal functions, intracranial MRI, many hypomelanotic 
changes, and angiofibromas found with dermatolog-
ical examination (7). 
There is no specific therapeutic approach for TS, 
and the treatment is symptomatic. Angiofibromas of 
the skin can be removed by dermabrasion or laser. 
Recent data show a good therapeutic effect of apply-
ing 0.1% rapamycin (8), which leads to a reduction of 
angiofibromas in patients with TS. On dermatologi-
cal follow up after five weeks of application of tacro-
limus, angiofibromas of the face were in regression. 
Some studies suggest the simultaneous topical ap-
plications of both of those drugs (9). In adolescents 
and adults of reproductive age, genetic counseling is 
recommended (10).
References:
1.  Northrup H, Krueger DA; International Tuberous 
Sclerosis Complex Consensus Group. Tuberous 
sclerosis complex diagnostic criteria update: re-
commendations of the 2012 International Tube-
rous Sclerosis Complex Consensus Conference. 
Pediatric Neurol. 2013;49:243-54.
2.  Au KS, Williams AT, Gambello MJ, Northrup H. 
Molecular genetic basis of tuberous sclerosis 
complex: from bench to bedside. J Child Neurol. 
2004;19:699-709.
3.  Cheng TS. Tuberous sclerosis complex: An update. 
Hong Kong J Dermatol Venereol. 2012;20:61-7. 
4.  Ebrahimi-Fakhari D, Saffari A, Wahlster L, Di Nar-
do A, Turner D, Lewis TL Jr, et al. Impaired Mi-
tochondrial Dynamics and Mitophagy in Neuro-
nal Models of Tuberous Sclerosis Complex. Cell 
Rep. 2016;17:1053-70.
5.  Cardis MA, De Klotz CMC. Cutaneous manifes-
tations of tuberous sclerosis complex and the 
paediatrician’s role. Arch Dis Child. 2017;102:858-
63.
6.  Midde ML, Saheb DM. Tuberous sclerosis complex 
– A case report. Southeast Asian J Case Rep Rew. 
2013;2:343-8.
7.  Schwartz RA, Fernández G, Kotulska K, Jóźwiak S. 
Tuberous sclerosis complex: advances in diagno-
sis, genetics, and management. J Am Acad Der-
matol. 2007;57:189-202.
8.  Wataya-Kaneda M, Tanaka M, Nakamura A, Mat-
sumoto S, Katayama I. A topical combination of 
rapamycin and tacrolimus for the treatment of 
angiofibroma due to tuberous sclerosis complex 
(TSC): a pilot study of nine Japanese patients with 
TSC of different disease severity. J Dermatology. 
2011;165:912-6.
9.  MacKeigan JP, Krueger DA. Differentiating mTOR 
inhibitors in TSC. Neuro-Oncology 2015;17:1550-
9.
10. Tsai V, Crino P. Tuberous sclerosis complex: genetic 
basis and management strategies. Adv Genomics 
Genet. 2012:19-31.
Mirjana Bakić¹, Marina Ratković², Branka 
Gledović², Balsa Vujović³, Danilo Radunović², 
Vera Babić¹, Vladimir Prelević²
1Clinic for Dermatology, Clinical Center of Monte-
negro, Podgorica, Montenegro; 2Clinic for Nephrology, 
Clinical Center of Montenegro, Podgorica, Montenegro; 
3Clinic for Neurology, Clinical Center of Montenegro, 
Podgorica, Montenegro
Corresponding author: 
Vladimir Prelević, MD 
Clinic for Nephrology





Received: July 23, 2017
Accepted: January 11, 2018
Letter to the editor Acta Dermatovenerol Croat
    2018;26(1):73-74
